gap project portfolio » TomegaVax

Project Title: CMV vectored vaccines against human papillomavirus (HPV) and characterization of their immune responses in Rhesus macaques

Principal Investigator: Klaus Früh, Ph.D., Oregon Health Sciences University

Company Principal: Eric Bruening, Ph.D., TomegaVax, Inc.

Description: TomegaVax is a biotechnology company focused on developing vaccines for critical unmet medical needs. It was founded by a world class team of scientists with expertise in virology, immunology, and vaccine development to commercialize the Cytomegalovirus vaccine platform developed at OHSU’s Vaccine and Gene Therapy Institute (VGTI).  Antigens delivered by CMV vectors induce a continuous low level stimulation of the immune system that results in an active T-cell mediated immune shield.  The platform technology is ideally suited to address targets such as HPV which can take decades to progress to cervical cancer, while remaining otherwise hidden from the immune system. CMV-based vaccines have demonstrated pre-clinical efficacy in some of the most debilitating diseases known to man including HIV, Ebola, and tuberculosis.  This proposal, combined with ongoing SBIR funded preclinical development of CMV vectors against HPV, will help establish the utility of the TomegaVax platform as a therapeutic cervical cancer vaccine.

« Back to portfolio list